COVID-19 Vaccination Guidance for People Who Are Immunocompromised

Introduction

COVID-19 vaccination is recommended for people ages 6 months and older who are moderately or severely immunocompromised. Moderate or severe immunocompromise is a risk factor for severe COVID-19. The recommended vaccine and number of 2026-2027 COVID-19 vaccine doses for people who are moderately or severely immunocompromised are based on age and vaccination history (Table 2).

Table 2: 2026–2027 COVID-19 vaccination schedule for people who are moderately or severely immunocompromised, November 4, 2025

2a: Ages 6 months–4 years

2b: Ages 5–11 years

2c: Ages 12 years and older

Self-attestation of immunocompromised status

People can self-attest to their moderately or severely immunocompromised status and receive COVID-19 vaccine doses wherever vaccines are offered. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation.

COVID-19 vaccination and pemivibart

Pemivibart (Pemgarda) is a monoclonal antibody for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination and who meet the Food and Drug Administration (FDA)-authorized conditions for use. Pemivibart is not authorized for treatment of COVID-19 or for post-exposure prophylaxis. Healthcare providers should consult the pemivibart fact sheet and frequently asked questions for additional information.

Pemivibart is not a substitute for COVID-19 vaccination. People who are moderately or severely immunocompromised should receive COVID-19 vaccine according to the recommended schedule. Per the pemivibart Emergency Use Authorization (EUA), administration of pemivibart should be deferred for at least 2 weeks after a dose of COVID-19 vaccine.

Description of moderate and severe immunocompromising conditions and treatment

Moderate and severe immunocompromising conditions and treatments include but are not limited to:

• Active treatment for solid tumor and hematologic malignancies

• Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)

• Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy

• Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)

• Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)

• Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection

• Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.

For additional information about the degree of immune suppression associated with different medical conditions and treatments, providers can consult General Best Practices for Immunizations, the CDC Yellow Book, and the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host.

Development of moderate or severe immunocompromise and revaccination

Development of moderate or severe immunocompromise after vaccination

People who were vaccinated for COVID-19 and subsequently become moderately or severely immunocompromised should follow the COVID-19 vaccination schedule in Table 2.

Considerations for revaccination

Recipients of HCT or CAR-T-cell therapy who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for people who are unvaccinated (Table 2).

Revaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies) according to the currently recommended schedule for people who are unvaccinated (Table 2). The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies.

A patient's clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination.

Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies

Administration of COVID-19 vaccines should not necessarily be delayed in patients taking immunosuppressive therapies. Whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy.

Timing of COVID-19 vaccination should take into consideration:

• Current or planned immunosuppressive therapies

• Optimization of both the patient's medical condition and anticipated response to vaccination

• Individual benefits and risks

On a case-by-case basis, providers caring for these patients may administer Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines through off-label use outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient who is immunocompromised.